![](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/21442236-739076220-cost-containment-targets-achieved-for-fy2024-and-continuing-100x58.jpeg)
Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024
NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an operational update and reported financial results for the period ended June 30 …